“…As with many of the ASMs, valproate has potential adverse events, which include potential hematological complications, carnitine depletion, hepatotoxicity, and increased body mass. 3,4 The product, first registered in 1973, was widely used as first-line intervention for focal and generalized seizures. Intrauterine exposure carries a two-to sevenfold increased risk of major congenital malformations, as well as poorer cognitive development in the offspring, and significantly increases the rate of autistic traits and autism.…”